Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless "First-in-Human" Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment

被引：0

作者：

De Bruyn, Steven ^{[1
]}

Gachalyi, Bela ^{[2
]}

Rojkovich, Bernadette ^{[3
]}

Bruk, Slavomir ^{[4
]}

Sramek, Petr ^{[5
]}

Korkosz, Mariusz ^{[6
]}

Krause, Krzysztof ^{[7
]}

Schoen, Pieter ^{[1
]}

Sargentini-Maier, Laura ^{[1
]}

D'Artois, Joke ^{[1
]}

Verschueren, Katrien ^{[1
]}

De Swert, Katelijne ^{[1
]}

Arold, Gerhard ^{[8
]}

Holz, Josefin-Beate ^{[1
]}

机构：

[1] Ablynx NV, Zwijnaarde, Belgium

[2] Peterfy Sandor Utcai Korhaz, Budapest, Hungary

[3] Budai Irgalmasrendi Korhaz Kht, Budapest, Hungary

[4] Nemocnice Trinec, Trinec, Czech Republic

[5] Pharmaceut Res Associates CZ, Prague, Czech Republic

[6] Szpital Uniwersytecki Krakowie, Krakow, Poland

[7] Wojewodzki Szpital, Wroclaw, Poland

[8] PRA Int GmbH, Berlin, Germany

来源：

ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1307

引用

页码：S561 / S561

页数：1

共 31 条

[21] RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT (SIRROUND-D)
Takeuchi, T.
Thorne, C.
Karpouzas, G.
Sheng, S.
Xu, W.
Rao, R.
Fei, K.
Hsu, B.
VALUE IN HEALTH, 2016, 19 (07) : A531 - A531
[22] Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson's disease: Topline results of the six-month double-blind placebo-controlled main study and the six-month active treatment extension study
Booms, S.
Huttunen, H.
Koskinen, J.
Sjogren, M.
Saarma, M.
Woolley, M.
Murphy, B.
Fielder, P.
Baker, J.
Skinner, P.
Rinne, J.
Varrone, A.
Andreasson, M.
Paul-Visse, G.
Kivisaari, R.
Bjartmarz, H.
Lind, G.
Almqvist, P.
Scheperjans, F.
Widner, H.
Svenningsson, P.
MOVEMENT DISORDERS, 2020, 35 : S390 - S390
[23] A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors
Yap, T. A.
Moore, K. N.
Patel, M.
Henick, B. S.
Do, D.
Iheanacho, A.
Zhang, H.
Roche, M.
Newberry, K.
Hsieh, A.
Juric, D.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S765 - S765
[24] RESULTS FROM A 2-PART, PROOF-OF-CONCEPT, DOSE-RANGING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SIRUKUMAB, A HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
Hsu, B.
Sheng, S.
Smolen, J. S.
Weinblatt, M. E.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 188 - 188
[25] Phase II study of low-dose methotrexate to reduce the incidence of human anti-mouse antibodies in patients receiving I-131 tositumomab as first-line treatment for follicular lymphoma.
Lebovic, Daniel
Avram, Anca M.
Dewaraja, Yuni
Estes, Judith
Jacobi, Kathryn
Goeman, Sara
Kyle, Sarah
Chapman, Erica
Griffith, Kent A.
Kaminski, Mark Stefan
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[26] First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts)
Leary, Alexandra
Awada, Ahmad
Delord, Jean-Pierre
Floquet, Anne
Ray-Coquard, Isabelle Laure
Abdeddaim, Cyril
Fabbro, Michel
Kalbacher, Elsa
Vergote, Ignace
Banerjee, Susana N.
Frenois, Francois-Xavier
Noel, Gregory
Lantz, Olivier
Cassard, Lydie
Coste, Agnes
Villard, Marine
Lemee, Fanny
Tabah-Fisch, Isabelle Marie
Le Tourneau, Christophe
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A☆02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101).
Blumenschein, George R., Jr.
Davar, Diwakar
Gutierrez, Rodolfo
Segal, Neil Howard
Johnson, Melissa Lynne
Dar, Mohammed M.
Marshall, Shannon
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[28] First-in-human phase 1A study of RGT-419B, a next generation CDK4 inhibitor, in patients (pts) with hormone receptor positive (HR+) HER2advanced/metastatic breast cancer (ABC) who progressed on prior CDK4/6 inhibitors (CDK4/6i)
Wander, Seth
Valacer, Dave
Zuniga, Richard
Yeckes-Rodin, Heather
Perkins, Christopher
Ge, Lisa
Yao, Lili
Lin, Jing
Begley, Dawn
Sun, Feifei
Zheng, Andie
Han, Jing
Xie, Zhi
Bardia, Aditya
Kalinsky, Kevin
CANCER RESEARCH, 2024, 84 (09)
[29] A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors
Sarker, Debashis
Banerji, Udai
Blagden, Sarah Patricia
Cook, Natalie
Evans, T. R. Jeffry
Plummer, Elizabeth Ruth
Braun, Marina
Cleverly, Ann
Diaz, Nieves
Jones, Paul
Matthews, Ivan
Glatt, Sophie
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[30] A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.
Finn, R. S.
Boer, K.
Lang, I.
Parikh, R. J.
Patel, R.
Schmidt, M.
Hagenstad, C. T.
Lim, H. J.
Pinter, T.
Amadori, D.
Chan, D.
Dichmann, R.
Kim, S. T.
Randolph, S.
Slamon, D. J.
Crown, J. P.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 →